Professor Jochen Seufert
University of Freiburg, Freiburg (Germany)
Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial
Event: ESC Congress 2018
Topic: Antidiabetic Pharmacotherapy
Session: Cardiac patients with comorbidities
ESC 365 is supported by
